期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

预防对比剂肾病药物的研究进展 被引量：2

Rsearch Progress on the Medicine Prevention of Contrast-induced Nephropathy
下载PDF
导出
摘要 对比剂肾病(CIN)是指血管内应用碘对比剂后发生的急性肾功能损害或肾功能损害加重。CIN是目前心导管手术的重要并发症,同时也是住院患者发生急性肾衰竭的第3位致病因素。CIN增加了心脏不良事件的风险和病死率,延长了患者住院时间。目前的指南对于CIN没有提出确切的治疗方法。该文就近年来对于预防CIN药物的研究进展予以综述。 Contrast-induced nephropathy（CIN） refers to the acute renal damage or renal impairment caused by the application of iodine contrast agent in blood vessels.CIN is the third leading cause of acute renal failure in hospitalized patients and a recognized complication of cardiac catheterization.CIN is associated with increased risk of adverse cardiovascular events and mortality,as well as prolonged hospitalization.Currently,there is no definite treatment for CIN in guidelines.Here is to make a review of the medicine used in the prevention of CIN in recent years.
作者 徐彧 王砚青 赵艳芳
机构地区 解放军
出处 《医学综述》 2014年第18期3347-3349,共3页 Medical Recapitulate
关键词 对比剂肾病 药物 进展 Contrast-induced nephropathy Medicine Progress
分类号 R543.5 [医药卫生—心血管疾病]
  • 相关文献

参考文献30

  • 1Stacul F,Adam A,Becker CR,et al.Strategies to reduce the risk of contrast-induced nephropathy[J].Am J Cardiol,2006,98(6):59-77.
  • 2Soma VR,Cavusoglu E,Vidhun R,et al.Contrast-associated nephropathy[J].Heart Dis,2002,4(6):372-379.
  • 3Asif A,Prestion RA,Rogh D.Radiocontrast-induced Nephropathy[J].Am J Ther,2003,10(2):137-147.
  • 4Nikolsky E,Mehran RJ.Hydration protocols to reduce the incidence of contrast-induced nephropathy[J].Invasive Cardiol,2008,20(10):527-538.
  • 5Shemirani H,Pourrmoghaddas M.A randomized trial of saline hydration to prevent contrast-induced nephropathy in patients on regular captopril or furosemide therapy undergoing percutaneous coronary intervention[J].Saudi J Kidney Dis Transpl,2012,23(2):280-285.
  • 6CalabròP,Bianchi R,Caprile M,et al.Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography[J].Minerva Cardioangiol,2010,58(1):35-40.
  • 7Kong DG,Hou YF,Ma LL,et al.Comparison of oral and intravenous hydration strategies for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography or angioplasty:a randomized clinical trial[J].Acta Cardiol,2012,67(5):565-569.
  • 8Gu GQ,Lu R,Cui W,et al.Low-dose furosemide administered with adequate hydration reduces contrast-induced nephropathy in patients undergoing coronary angiography[J].Cardiology,2013,125(2):69-73.
  • 9Marenzi G,Ferrari C,Marana I,et al.Prevention of contrast nephropathy by furosemide with matched hydration:the MYTHOS(Induced Diuresis with Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention)trial[J].JACC Cardiovasc Interv,2012,5(1):90-97.
  • 10Kapoor A,Kumar S,Gulati S,et al.The role of theophylline in contrast-induced nephropathy:a case-control study[J].Nephrol Dial Transplant,2002,17(11):1936-1941.

二级参考文献12

  • 1Aspelin P.Nephrotoxicity and the role of contrast media.Radiat Med,2004,22:377-378.
  • 2Nash K,Hafeez A,Hou S.Hospital-acquired renal insufficiency.Am J Kidney Dis,2002,39:930-936.
  • 3Taylor AJ,Hotehkiss D,Morse RW,et al.PREPARED:Preparation for Angiography in Renal Dysfunction:a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction.Chest,1998,114:1570-1574.
  • 4Mueller C,Buerkle G,Buettner HJ,et al.Prevention of contrast media-associated nephropathy:randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty.Arch Intern Med,2002,162:329-336.
  • 5Shepherd J,Kastelein JJ,Bittner V,et al.Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease:the Treating to New Targets (TNT) study.Clin J Am Soc Nephrol,2007,2:1131-1139.
  • 6王笑云.肾小球功能检查//陈文彬,潘祥林.诊断学.6版.北京:人民卫生出版社,2004:379
  • 7Chello M,Goffredo C,Patti G,Effects of atorvestatin on arterial endothelial function in coronary bypass surgery.Eur J Cardiothorac Surg,2005,28:805-810.
  • 8Patti G,Nusea A,Chello M,et al.Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing pereutaneous coronary intervention.Am J Cardiol,2008,101:279-285.
  • 9Dulak J,Loboda A,Jazwa A.Atorvastatin affects several angiogenic mediators in human endothelial cells.Endothelium,2005,12:233-241.
  • 10Bonnet J,McPherson R,Tedgui A,et al.Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease:results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.Clin Ther,2008,30:2298-2313.

共引文献46

同被引文献17

  • 1Jaffery Z, Verma A, White C J, et al. A randomized trial of intra- venous n-acetylcysteine to prevent contrast induced nephrepathy in acute coronary syndromes [ J ]. Catheter Cardiovasc Interv, 2012, 79(6) :921-926.
  • 2Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial [ J ]. JAMA, 2003,289 ( 5 ) :553-558.
  • 3Berwanger O, Cavalcanti AB, Sousa AM, et al. Acetylcysteine for the prevention of renal outcomes in patients with diabetes mellitus undergoing coronary and peripheral vascular angiography: a sub- study of the acetylcysteine for contrast-induced nephropathy trial[J]. Cire Cardiovasc Interv, 2013,6(2) :139-145.
  • 4Shyu KG, Cheng JJ, Kuan P. Aeetyleysteine protects against acute re- nal damage in patients with abnormal renal function undergoing a coro- nary procedure[J]. J Am Con Cardiol, 2002,40(8) :1383-1388.
  • 5Kim B J, Sung KC, Kim BS, et al. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography ( ENABLE Study) : a prospective, randomized trial[J]. Int J Car- did, 2010,138(3) :239-245.
  • 6Seyon RA, Jensen LA, Ferguson IA, et al. Efficacy of N-aeetyl- cysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary in- tervention[J]. Heart Lung, 2007,36(3) :195-204.
  • 7Comes VO, Polide Figueredo CE, Caramori P, et al. N-acetylcys- teine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial[ J ]. Heart, 2005,91 (6) :774-778.
  • 8Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-in- duced ncphropathy following coronary angiography. A randomized controlled trial and review of the current literature[ J]. Eur Heart J, 2004,25(3) :212-218.
  • 9Baranska-Kosakowska A, Zakliczynski M, Przybylski R, et al. Role of N-acetylcysteine on renal function in patients after ortho- topic heart transplantation undergoing coronary angiography [ J]. Transplant Proc, 2007,39 (9) :2853-2855.
  • 10Calabro P, Bianchi R, Crisci M, et al. Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced ne- phropathy in low-risk populations undergoing coronary artery angi- ography[J]. Intern Emerg Med, 2011,6(6) :503-507.

引证文献2

二级引证文献4

医学综述
2014年 第18期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部